Tosi, Diego http://orcid.org/0000-0003-0401-7400
Pérez-Gracia, Esther
Atis, Salima
Vié, Nadia
Combès, Eve
Gabanou, Mélissa
Larbouret, Christel
Jarlier, Marta
Mollevi, Caroline
Torro, Adeline
Del Rio, Maguy
Martineau, Pierre
Gongora, Céline
Funding for this research was provided by:
Novartis SAS
SIRIC Montpellier
LabEx MabImprove
Article History
Received: 13 December 2017
Accepted: 31 July 2018
First Online: 13 August 2018
Ethics approval and consent to participate
: All animal experiments received specific ethical committee approval from the Languedoc-Roussillon Ethics Committee for Animal Experimentation, Faculty of Pharmacy, Montpellier University, Montpellier, France (approval code CEEA-LR- 12104), and were performed in an accredited establishment (Institut régional du Cancer de Montpellier, Montpellier, France; IRCM accreditation code: C34–172-27; Dr. Céline Gongora, accreditation code: 34–142) in compliance with the French regulations and ethical guidelines for experimental animal studies, over and above general adherence to guidelines.
: Not applicable.
: Dr. Diego Tosi received sponsorship from Novartis and Sandoz for attending international meetings in 2010, 2012 and 2013. The authors do not have any other relevant conflict of interest to declare.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.